US 12,239,704 B2
Recombinant non-pathogenic Marek's disease virus constructs encoding multiple heterologous antigens
Stephanie M. Cook, Omaha, NE (US); Mohamad Morsey, Omaha, NE (US); and Ian Tarpey, St. Ives (GB)
Assigned to INTERVET INC., Rahway, NJ (US)
Filed by Intervet Inc., Madison, NJ (US)
Filed on Dec. 7, 2021, as Appl. No. 17/544,044.
Application 17/544,044 is a continuation of application No. 16/753,133, granted, now 11,229,698, previously published as PCT/EP2018/077725, filed on Oct. 11, 2018.
Claims priority of provisional application 62/729,673, filed on Sep. 11, 2018.
Claims priority of provisional application 62/571,524, filed on Oct. 12, 2017.
Prior Publication US 2022/0088187 A1, Mar. 24, 2022
Int. Cl. A61K 39/255 (2006.01); A61K 39/00 (2006.01); A61K 39/17 (2006.01); A61P 31/20 (2006.01); C12N 15/86 (2006.01)
CPC A61K 39/255 (2013.01) [A61K 39/17 (2013.01); A61P 31/20 (2018.01); C12N 15/86 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/552 (2013.01); A61K 2039/70 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A recombinant herpesvirus of turkeys (rHVT) that comprises a first heterologous nucleic acid and a second heterologous nucleic acid;
wherein the first heterologous nucleic acid is located in a first nonessential site in the rHVT genome, and the second heterologous nucleic acid is located in a second nonessential site in the rHVT genome;
wherein the first nonessential site is the UL54.5 site and the second nonessential site is the US2 site;
wherein the first heterologous nucleic acid encodes an Infectious Bursal Disease Virus viral protein 2 (IBDV VP2), an Infectious Laryngotracheitis Virus glycoprotein D (ILTV gD) and an Infectious Laryngotracheitis Virus glycoprotein I (ILTV gI), and wherein the second heterologous encodes a Newcastle Disease Virus fusion protein (NDV F); and
wherein the first heterologous nucleic acid is configured to be transcribed in the opposite direction relative to a UL54.5 gene of the rHVT.